Chemomab Therapeutics Ltd
NASDAQ:CMMB

Watchlist Manager
Chemomab Therapeutics Ltd Logo
Chemomab Therapeutics Ltd
NASDAQ:CMMB
Watchlist
Price: 1.55 USD -1.27% Market Closed
Market Cap: $8.2m

Chemomab Therapeutics Ltd
Investor Relations

Chemomab Therapeutics Ltd. operates as a clinical-stage biotech company. The firm specializes in the development of patient oriented targeted therapy for the treatment of a wide range of cancers. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q1 2023
Call Date
May 11, 2023
Q1 2023 Earnings Call
No Analysis Available

This earnings call has not been analyzed yet.

If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.

Request Earnings Call Analysis
Earnings Call Recording
Other Earnings Calls
2023

Management

Dr. Adi Mor George Ph.D.
Co-Founder, Chief Scientific Officer, CEO & Executive Director
No Bio Available
Ms. Sigal Fattal CPA, M.B.A.
Chief Financial Officer
No Bio Available
Dr. Matthew B. Frankel M.B.A., M.D.
Chief Medical Officer & VP of Drug Development
No Bio Available
Barbara Lindheim
Consulting Vice President of Investor & Public Relations, Strategic Communications
No Bio Available
Mr. Jack Lawler
Senior VP of Global Clinical Development Operations
No Bio Available

Contacts

Address
TEL AVIV-YAFO
Kiryat Atidim, Building 7
Contacts